Graphite Bio, Inc.

As of July 30, 2025, Graphite Bio, Inc. is considered risky and overvalued due to negative financial metrics, despite strong stock performance, especially when compared to its peer, Stoke Therapeutics, Inc.

As of May 9, 2024, the market trend is neutral with a balance in momentum, showing bullish indicators on weekly and monthly charts but tempered by a mildly bearish Dow Theory stance and uncertainty from RSI and OBV signals.

Graphite Bio, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $15 million and a market cap of $796.43 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -24.86%.

As of Jun 18, Graphite Bio, Inc. has a market capitalization of 796.43 million and reported net sales of 0.00 million with a net profit of -47.73 million over the last four quarters. Shareholder's funds were 204.08 million, and total assets were 215.30 million.